Blue Earth Therapeutics doses first participant in Phase 1 trial of Actinium (²²⁵Ac) rhPSMA-10.1 Injection for advanced prostate cancer
Friday, July 10, 2026
Blue Earth Therapeutics and University College London (UCL) have dosed the first participant in a Phase 1 clinical trial evaluating Actinium (²²⁵Ac) rhPSMA-10.1 Injection, an investigational prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical for patients with metastatic castration-resistant prostate cancer (mCRPC).
The Phase 1 study (NCT07414940), sponsored by UCL and being conducted at University College London Hospital in London, is supported by Blue Earth Therapeutics, which is providing funding and the investigational medicine.
The trial will assess the safety and anti-tumour activity of Actinium (²²⁵Ac) rhPSMA-10.1 Injection in patients with PSMA-positive mCRPC whose disease has progressed after previous treatment. The findings are expected to help identify potential side effects and support dose selection for future clinical studies.
Actinium-225 is an alpha-emitting radionuclide that delivers high-energy radiation over a very short distance. This approach is designed to cause irreparable DNA damage in targeted cancer cells while reducing exposure to surrounding healthy tissue. Combined with the PSMA-targeting molecule rhPSMA-10.1, the therapy is intended to deliver radiation directly to prostate cancer lesions, offering a targeted treatment option for patients with advanced disease.
Actinium (²²⁵Ac) rhPSMA-10.1 Injection is the second clinical candidate in Blue Earth Therapeutics’ oncology pipeline. It follows the company’s Lutetium (¹⁷⁷Lu) rhPSMA-10.1 Injection programme, which is currently being evaluated in a Phase 2 clinical trial. Together, the programmes support the company’s development of both alpha- and beta-emitting radiopharmaceutical therapies using its radiohybrid PSMA platform.
Blue Earth Therapeutics said the study marks an important milestone in the development of its radiopharmaceutical pipeline and strengthens its collaboration with UCL to advance targeted treatment options for patients with advanced prostate cancer.
Source: prnewswire.com
